VSTM – verastem, inc. (US:NASDAQ)

News

Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026 [Yahoo! Finance]
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
Verastem (VSTM) had its "sell (d-)" rating reaffirmed by Weiss Ratings.
Verastem (VSTM) had its "buy" rating reaffirmed by BTIG Research. They now have a $19.00 price target on the stock.
Vectoring In On Verastem [Seeking Alpha]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com